<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61977">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02299089</url>
  </required_header>
  <id_info>
    <org_study_id>HS-12-455</org_study_id>
    <nct_id>NCT02299089</nct_id>
  </id_info>
  <brief_title>Phase II Study of Subcutaneous Injection Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)</brief_title>
  <official_title>A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Two Patient Groups With Acromegaly and Neuroendocrine Tumours (NETs) Previously Treated With Sandostatin® LAR®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Camurus AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Camurus AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy,
      and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a
      functional, well-differentiated NET, with carcinoid symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, open-label multicentre, randomised study to assess the PK, PD, efficacy,
      and safety of two dosing regimens of CAM2029 in adult patients with acromegaly or a
      functional, well-differentiated NET, with carcinoid symptoms, treated for at least 2 months
      with Sandostatin LAR at doses of 10 mg, 20 mg, or 30 mg before the start of the Sandostatin
      LAR Last Dose Assessment Phase (Day -28).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile of octreotide after each injection of CAM2029 as compared with baseline PK for Sandostatin® Long-acting Release (LAR®)</measure>
    <time_frame>Baseline, Day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events and serious adverse events</measure>
    <time_frame>Baseline, Day 84</time_frame>
    <description>Safety of repeat dose of CAM2029</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAM2029 effect on insulin-like growth factor (IGF-1) (Acromegaly)</measure>
    <time_frame>Baseline, Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CAM2029 effect on growth hormone (GH) (Acromegaly)</measure>
    <time_frame>Baseline, Day 84</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess the symptoms of carcinoid syndrome (number of bowel movements and flushing) and the use of rescue medication versus baseline (by using patient diaries) (NET)</measure>
    <time_frame>Baseline, Day 84</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Acromegaly</condition>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>CAM2029 10 mg (NET)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAM2029 20 mg (NET)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAM2029 10 mg (Acromegaly)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAM2029 20 mg (Acromegaly)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>octreotide FluidCrystal® injection depot</intervention_name>
    <arm_group_label>CAM2029 10 mg (NET)</arm_group_label>
    <arm_group_label>CAM2029 20 mg (NET)</arm_group_label>
    <arm_group_label>CAM2029 10 mg (Acromegaly)</arm_group_label>
    <arm_group_label>CAM2029 20 mg (Acromegaly)</arm_group_label>
    <other_name>CAM2029</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Acromegaly:

          -  Male or female patients ≥18 years of age

          -  Acromegaly currently treated with Sandostatin LAR

        NET:

          -  Male or female patients ≥18 years of age

          -  Functional, well-differentiated (Grade 1 or Grade 2) NET with symptoms of carcinoid
             syndrome (number of bowel movements and/or flushing)

          -  Currently treated with Sandostatin LAR for symptom control

        Exclusion Criteria:

        Acromegaly:

          -  Inadequate bone marrow function

          -  Abnormal coagulation or chronic treatment with warfarin or coumarin derivates

          -  Impaired liver, cardiac and/or renal function

          -  Known gallbladder, bile duct disease or pancreatitis

          -  Diabetes with poorly controlled blood glucose levels despite adequate therapy

          -  Hypothyroidisms not adequately treated

        NET:

          -  Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma,
             adenocarcinoid, pancreatic islet cell carcinoma, insulinoma, glucagonoma, gastrinoma,
             goblet cell carcinoid, typical and atypical lung carcinoids, large cell
             neuroendocrine carcinoma and small cell carcinoma

          -  Carcinoid syndrome refractory to treatment with conventional doses of somatostatin
             analogues (SSAs)

          -  Inadequate bone marrow function

          -  Abnormal coagulation or chronic treatment with warfarin or coumarin derivates

          -  Impaired liver, cardiac and/or renal function

          -  Known gallbladder, bile duct disease or pancreatitis

          -  Short-bowel syndrome

          -  Diabetics with poorly controlled blood glucose levels despite adequate therapy

          -  Hypothyroidism, not adequately treated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Pavel, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Campus Virchow Klinikum, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rouen, Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abteilung: Klinische Studien</name>
      <address>
        <city>Bad Berka</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCCS Azienda Ospedaliera Universitaria San Martino IST</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Irccs Ca' Granda</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Napoli Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 8, 2016</lastchanged_date>
  <firstreceived_date>November 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acromegaly</keyword>
  <keyword>neuroendocrine tumour (NET)</keyword>
  <keyword>carcinoid syndrome</keyword>
  <keyword>octreotide</keyword>
  <keyword>Sandostatin LAR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
